ミエロマトーシスにおけるインターフェロン療法

Cytogenetic evolution patterns in non-Hodgkin's lymphoma.

Blood·1995

Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors.

The journals of gerontology. Series A, Biological sciences and medical sciences·1995

Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.

The Journal of infectious diseases·1995

Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus.

Neuroscience letters·1995

Cytogenetically detected clonal heterogeneity in a duodenal adenocarcinoma.

Cancer genetics and cytogenetics·1995

Human papillomavirus in cell samples from Stockholm Gynecologic Health Screening.

Acta cytologica·1995

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Correction: An integrated automated deep learning framework for annotating tumor-infiltrating lymphocytes in lung adenocarcinoma pathology.

Frontiers in bioinformatics·2026

Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.

Frontiers in allergy·2026

Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

Crohn's & colitis 360·2026

A pipeline for cell migration analysis in live-cell imaging data from human iPSC-derived forebrain assembloids.

Frontiers in cell and developmental biology·2026

Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.

Frontiers in immunology·2026

Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.

Frontiers in immunology·2026

関連する実験動画

ミエロマトーシスにおけるインターフェロン療法

関連する概念動画

Cytogenetic evolution patterns in non-Hodgkin's lymphoma.

Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors.

Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.

Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus.

Cytogenetically detected clonal heterogeneity in a duodenal adenocarcinoma.

Human papillomavirus in cell samples from Stockholm Gynecologic Health Screening.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Correction: An integrated automated deep learning framework for annotating tumor-infiltrating lymphocytes in lung adenocarcinoma pathology.

Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.

Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

A pipeline for cell migration analysis in live-cell imaging data from human iPSC-derived forebrain assembloids.

Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.

Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.

関連する実験動画

ミエロマトーシスにおけるインターフェロン療法

関連する概念動画

関連記事